Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma

Growth Factor ◽

Epidermal Growth Factor ◽

Colorectal Carcinoma ◽

Growth Factor Receptor ◽

Line Treatment ◽

Metastatic Colorectal Carcinoma ◽

First Line ◽

Epidermal Growth ◽

702 PUBLICATION Cetuximab and irinotecan/5-fluorouracil (5-FU)/folinic acid (FA) (AIO) is active and safe in the first-line treatment of metastatic colorectal cancer (mCRC) expressing the epidermal growth factor receptor (EGFR)

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(05)80997-8 ◽

2005 ◽

Vol 3 (2) ◽

pp. 199

Keyword(s):

Colorectal Cancer ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Metastatic Colorectal Cancer ◽

Growth Factor Receptor ◽

Line Treatment ◽

First Line ◽

Epidermal Growth ◽

An international phase II study of cetuximab in combination with oxaliplatin/5-fluorouracil (5-FU)/folinic acid (FA) (FOLFOX-4) in the first-line treatment of patients with metastatic colorectal cancer (CRC) expressing Epidermal Growth Factor Receptor (EGFR). Preliminary results

10.1200/jco.2004.22.90140.3512 ◽

2004 ◽

Vol 22 (14_suppl) ◽

pp. 3512-3512 ◽

Cited By ~ 4

Author(s):

J. M. Tabernero ◽

E. Van Cutsem ◽

J. Sastre ◽

A. Cervantes ◽

J.-L. Van Laethem ◽

...

Keyword(s):

Colorectal Cancer ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Phase Ii Study ◽

Growth Factor Receptor ◽

Line Treatment ◽

First Line ◽

Epidermal Growth ◽

Cetuximab in combination with oxaliplatin/5-fluorouracil (5-FU)/folinic acid (FA) (FOLFOX-4) in the first-line treatment of patients with epidermal growth factor receptor (EGFR)-expressing metastatic colorectal cancer: An international phase II study

10.1200/jco.2005.23.16_suppl.3535 ◽

2005 ◽

Vol 23 (16_suppl) ◽

pp. 3535-3535 ◽

Cited By ~ 42

Author(s):

E. Díaz Rubio ◽

J. Tabernero ◽

E. van Cutsem ◽

A. Cervantes ◽

T. André ◽

...

Keyword(s):

Colorectal Cancer ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Phase Ii Study ◽

Growth Factor Receptor ◽

Line Treatment ◽

First Line ◽

Epidermal Growth ◽

Efficacy of icotinib versus traditional chemotherapy as first-line treatment for preventing brain metastasis from advanced lung adenocarcinoma in patients with epidermal growth factor receptor-sensitive mutation

Journal of Cancer Research and Therapeutics ◽

10.4103/0973-1482.145851 ◽

2014 ◽

Vol 10 (7) ◽

pp. 155 ◽

Cited By ~ 4

Author(s):

Fang Li ◽

Nan Du ◽

Xiao Zhao ◽

Guangqin Zhu ◽

Huoming Chen ◽

...

Keyword(s):

Growth Factor ◽

Epidermal Growth Factor ◽

Brain Metastasis ◽

Lung Adenocarcinoma ◽

Growth Factor Receptor ◽

Line Treatment ◽

First Line ◽

Epidermal Growth ◽

Efficacy of Second-Line Bevacizumab-Containing Chemotherapy for Patients with Metastatic Colorectal Cancer following First-Line Treatment with an Anti-Epidermal Growth Factor Receptor Antibody

Oncology ◽

10.1159/000453336 ◽

2017 ◽

Vol 92 (4) ◽

pp. 205-212 ◽

Cited By ~ 2

Author(s):

Hiroko Hasegawa ◽

Hiroya Taniguchi ◽

Seiichiro Mitani ◽

Toshiki Masuishi ◽

Azusa Komori ◽

...

Keyword(s):

Colorectal Cancer ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Growth Factor Receptor ◽

Line Treatment ◽

Second Line ◽

First Line ◽

Epidermal Growth ◽

Abstract CT045: Ribociclib + letrozole for first-line treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): efficacy by baseline tumor markers

10.1158/1538-7445.am2017-ct045 ◽

2017 ◽

Cited By ~ 5

Author(s):

Fabrice Andre ◽

Salomon M. Stemmer ◽

Mario Campone ◽

Katarina Petrakova ◽

Shani Paluch-Shimon ◽

...

Keyword(s):

Breast Cancer ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Growth Factor Receptor ◽

Line Treatment ◽

First Line ◽

Hormone Receptor Positive ◽

Epidermal Growth ◽

An international phase II study of cetuximab in combination with oxaliplatin/5-fluorouracil (5-FU)/folinic acid (FA) (FOLFOX-4) in the first-line treatment of patients with metastatic colorectal cancer (CRC) expressing Epidermal Growth Factor Receptor (EGFR). Preliminary results

10.1200/jco.2004.22.14_suppl.3512 ◽

2004 ◽

Vol 22 (14_suppl) ◽

pp. 3512-3512 ◽

Cited By ~ 24

Author(s):

J. M. Tabernero ◽

E. Van Cutsem ◽

J. Sastre ◽

A. Cervantes ◽

J.-L. Van Laethem ◽

...

Keyword(s):

Colorectal Cancer ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Phase Ii Study ◽

Growth Factor Receptor ◽

Line Treatment ◽

First Line ◽

Epidermal Growth ◽

Bevacizumab for the first-line treatment of human epidermal growth factor receptor 2-negative advanced breast cancer

Current Opinion in Oncology ◽

10.1097/01.cco.0000397417.75245.9c ◽

2011 ◽

Vol 23 ◽

pp. S3-S9 ◽

Cited By ~ 8

Author(s):

Margarida Damasceno

Keyword(s):

Breast Cancer ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Advanced Breast Cancer ◽

Growth Factor Receptor ◽

Line Treatment ◽

First Line ◽

Epidermal Growth ◽

Phase I study of the humanized epidermal growth factor receptor (EGFR) antibody EMD 72000 (matuzumab) in combination with ECX (epirubicin, cisplatin and capecitabine) as first line treatment for advanced oesophagogastric (OG) adenocarcinoma

10.1200/jco.2005.23.16_suppl.4028 ◽

2005 ◽

Vol 23 (16_suppl) ◽

pp. 4028-4028 ◽

Cited By ~ 6

Author(s):

S. Rao ◽

N. Starling ◽

M. Benson ◽

A. Massey ◽

A. Wotherspoon ◽

...

Keyword(s):

Growth Factor ◽

Epidermal Growth Factor ◽

Phase I Study ◽

Growth Factor Receptor ◽

Line Treatment ◽

First Line ◽

Epidermal Growth ◽

First Line Treatment ◽

Egfr Antibody

Cost-effectiveness of epidermal growth factor receptor mutation testing and first-line treatment with gefitinib for patients with advanced adenocarcinoma of the lung

Cancer ◽

10.1002/cncr.26372 ◽

2011 ◽

Vol 118 (4) ◽

pp. 1032-1039 ◽

Cited By ~ 45

Author(s):

Gilberto de Lima Lopes ◽

Joel E. Segel ◽

Daniel S. W. Tan ◽

Young K. Do ◽

Tony Mok ◽

...

Keyword(s):

Cost Effectiveness ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Growth Factor Receptor ◽

Line Treatment ◽

First Line ◽

Adenocarcinoma Of The Lung ◽

Epidermal Growth ◽